---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-000253"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T14:37:37.445971+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioventus completes divestiture of Advanced Rehab business to Accelmed for $25M cash plus $20M earn-out

## Summary
- Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.
- Received $25M cash at closing, subject to working capital adjustments.
- Up to $20M in earn-out payments based on 2025-2026 revenue and EBITDA thresholds.
- Net closing proceeds of approx $20M to enhance liquidity; company to focus on core businesses.
- Accelmed is a private equity firm focused on commercial-stage HealthTech companies.

## SEC filing metadata
- accession: 0001628280-25-000253
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828025000253/0001628280-25-000253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828025000253/bvs-20241231.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-000253
- JSON: https://secwatch.observer/filing/0001628280-25-000253.json
- Plain text: https://secwatch.observer/filing/0001628280-25-000253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.